Standard BioTools
LAB
121 hedge funds and large institutions have $220M invested in Standard BioTools in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 33 increasing their positions, 44 reducing their positions, and 19 closing their positions.
95% more call options, than puts
Call options by funds: $1.92M | Put options by funds: $987K
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
2% more funds holding
Funds holding: 119 → 121 (+2)
3.39% less ownership
Funds ownership: 76.98% → 73.59% (-3.4%)
25% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 44
43% less capital invested
Capital invested by funds: $387M → $220M (-$166M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.78M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.31M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.08M |
| 4 |
NIM
Needham Investment Management
New York
|
+$1.05M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$897K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$10.6M |
| 2 |
O
OrbiMed
New York
|
-$3.65M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.64M |
| 4 |
Two Sigma Investments
New York
|
-$1.13M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$889K |
LAB Hedge Fund Activity: Q4 2021 in Review
121 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2021, worth a combined $220M — down 43% from $387M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new LAB positions and 19 closed out — a net gain of 3 holders — while 33 added to existing stakes and 44 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $1.78M. The largest seller was Millennium Management, cutting an estimated $10.6M.
- 121 institutional investors held Standard BioTools (LAB) as of Q4 2021, up from 119 in Q3 2021.
- Funds reported $220M of Standard BioTools stock for Q4 2021, down 43% quarter-over-quarter.
- 22 funds opened new Standard BioTools positions in Q4 2021 and 19 closed out, a net change of +3 holders.
- The largest Standard BioTools buyer in Q4 2021 was Balyasny Asset Management, an estimated $1.78M added.
- The largest Standard BioTools seller in Q4 2021 was Millennium Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q4 2021.